Verastem
Inc. (Nasdaq: VSTM) stopped enrollment in a Phase 2 registration-directed,
double-blind, placebo-controlled study of VS-6063 for patients with
mesothelioma sending the stock price plummeting $3.82 to close at $1.85.
Verastem halts enrollment in study
September 28, 2015 at 17:28 PM EDT